The antiparasitic drug ivermectin is approved for persons > 15 kg in the US and EU. A pharmacometric (PMX) population model with clinical PK data was developed (i) to characterize the effect of the patient-friendly ivermectin formulation CHILD-IVITAB on the absorption process and (ii) to evaluate dosing for studies in children < 15 kg. Simulations were performed to identify dosing with CHILD-IVITAB associated with similar exposure coverage in children ≥ 15 kg and < 15 kg as observed in adults receiving the reference formulation STROMECTOL ^® . A total of 448 ivermectin concentrations were available from 16 healthy adults. The absorption rate constant was 2.41 h ^-1 (CV 19%) for CHILD-IVITAB vs. 1.56 h ^-1 (CV 43%) for STROMECTOL ^® . Simulations indicated that 250 µg/kg of CHILD-IVITAB is associated with exposure coverage in children < 15 kg consistent with that observed in children ≥ 15 kg and adults receiving 200 µg/kg of STROMECTOL ^® . Performed analysis confirmed that CHILD-IVITAB is associated with faster and more controlled absorption than STROMECTOL ^® . Simulations indicate that 250 µg/kg of CHILD-IVITAB achieves equivalent ivermectin exposure coverage in children < 15 kg as seen in children ≥ 15 kg and adults.